Skip to main content
Premium Trial:

Request an Annual Quote

Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests

NEW YORK – Diagnostic firm SpeeDx announced Tuesday a partnership with Roche to expand global access to the firm's infectious disease and antibiotic resistance tests and technology.

Under the non-exclusive agreement, Roche will have access to SpeeDx's existing tests and technology, expanding patient access to diagnostic products, including new ones, for the management of antibiotic resistance in sexually transmitted infections, the firm said in a statement.

Financial and other terms of the deal were not disclosed. 

Sydney, Australia-based SpeeDx currently offers multiplex qPCR tests for gonorrhea and Mycoplasma genitalium, which the firm noted are listed by the US Centers for Disease Control and Prevention as key threats because of the rise of antibiotic resistance and limited treatment options. The tests help physicians choose targeted therapies for patients based on the resistance status of their infections, the company said.

Last year, SpeeDx received CE-IVD marking for its M. gen test on the Cepheid FleXible cartridge detecting M. gen and five markers of resistance to the macrolide antibiotic azithromycin. Earlier this year, the firm partnered with Laboratory Corporation of America to codevelop diagnostic tests for women's health and infectious disease indications.